Currently, an ongoing clinical trial is evaluating the concurrent infusion of CD19-specific CAR-T cells together with rituximab in patients with refractory B-cell lymphoma (NCT04002401). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.